Merus Labs International Inc (MSL) Receives Consensus Recommendation of “Hold” from Analysts

Merus Labs International Inc (TSE:MSL) (NASDAQ:MSLI) has been assigned an average rating of “Hold” from the seven analysts that are currently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is C$1.99.

A number of equities analysts have recently weighed in on the stock. Scotiabank lifted their price target on shares of Merus Labs International from C$1.25 to C$1.65 and gave the stock a “sector perform” rating in a research report on Friday, May 12th. TD Securities reduced their price target on shares of Merus Labs International from C$3.00 to C$1.65 and set a “tender” rating on the stock in a research report on Friday, May 12th. Finally, CIBC lifted their price target on shares of Merus Labs International from C$1.40 to C$1.65 in a research report on Monday, May 15th.

TRADEMARK VIOLATION NOTICE: “Merus Labs International Inc (MSL) Receives Consensus Recommendation of “Hold” from Analysts” was originally posted by BBNS and is the sole property of of BBNS. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://baseballnewssource.com/markets/merus-labs-international-inc-msl-receives-consensus-recommendation-of-hold-from-analysts/1409287.html.

Shares of Merus Labs International (TSE:MSL) traded up 0.61% during mid-day trading on Tuesday, reaching $1.65. 21,976 shares of the company’s stock traded hands. The company’s 50 day moving average is $1.63 and its 200-day moving average is $1.30. Merus Labs International has a 52 week low of $0.95 and a 52 week high of $1.76.

Merus Labs International Company Profile

Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.

Analyst Recommendations for Merus Labs International (TSE:MSL)

Receive News & Ratings for Merus Labs International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International Inc and related companies with our FREE daily email newsletter.

 


Latest News

Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury
Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras
Cleveland Indians Acquire Jay Bruce From New York Mets
Cleveland Indians Acquire Jay Bruce From New York Mets


Leave a Reply

 
© 2006-2017 BBNS.